- Home
- CBIO vs NVX Comparison
CBIO vs NVX Comparison
Compare CBIO & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- NVX
- Stock Information
- Founded
- CBIO 2003
- NVX 2012
- Country
- CBIO United States
- NVX Australia
- Employees
- CBIO N/A
- NVX N/A
- Industry
- CBIO
- NVX Industrial Machinery/Components
- Sector
- CBIO
- NVX Miscellaneous
- Exchange
- CBIO Nasdaq
- NVX Nasdaq
- Market Cap
- CBIO 219.5M
- NVX 204.1M
- IPO Year
- CBIO N/A
- NVX N/A
- Fundamental
- Price
- CBIO $13.07
- NVX $1.03
- Analyst Decision
- CBIO Strong Buy
- NVX
- Analyst Count
- CBIO 5
- NVX 0
- Target Price
- CBIO $25.60
- NVX N/A
- AVG Volume (30 Days)
- CBIO 65.2K
- NVX 2.8M
- Earning Date
- CBIO 11-06-2025
- NVX 01-01-0001
- Dividend Yield
- CBIO N/A
- NVX N/A
- EPS Growth
- CBIO N/A
- NVX N/A
- EPS
- CBIO N/A
- NVX N/A
- Revenue
- CBIO N/A
- NVX $5,931,433.00
- Revenue This Year
- CBIO N/A
- NVX $165.90
- Revenue Next Year
- CBIO N/A
- NVX $1,344.85
- P/E Ratio
- CBIO N/A
- NVX N/A
- Revenue Growth
- CBIO N/A
- NVX N/A
- 52 Week Low
- CBIO $9.81
- NVX $0.81
- 52 Week High
- CBIO $21.40
- NVX $3.86
- Technical
- Relative Strength Index (RSI)
- CBIO 59.79
- NVX 35.34
- Support Level
- CBIO $12.76
- NVX $0.96
- Resistance Level
- CBIO $13.43
- NVX $1.24
- Average True Range (ATR)
- CBIO 0.46
- NVX 0.08
- MACD
- CBIO 0.01
- NVX -0.01
- Stochastic Oscillator
- CBIO 77.78
- NVX 24.17
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.